[go: up one dir, main page]

WO2008108908A2 - Cosmétique de 1,2-benzènedicarboxylate d'acétate de cellulose - Google Patents

Cosmétique de 1,2-benzènedicarboxylate d'acétate de cellulose Download PDF

Info

Publication number
WO2008108908A2
WO2008108908A2 PCT/US2008/001542 US2008001542W WO2008108908A2 WO 2008108908 A2 WO2008108908 A2 WO 2008108908A2 US 2008001542 W US2008001542 W US 2008001542W WO 2008108908 A2 WO2008108908 A2 WO 2008108908A2
Authority
WO
WIPO (PCT)
Prior art keywords
solution
weight
benzenedicarboxylate
acne
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/001542
Other languages
English (en)
Other versions
WO2008108908A3 (fr
Inventor
Nathan Strick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Publication of WO2008108908A2 publication Critical patent/WO2008108908A2/fr
Anticipated expiration legal-status Critical
Publication of WO2008108908A3 publication Critical patent/WO2008108908A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90—Block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
    • A61K2800/5422—Polymers characterized by specific structures/properties characterized by the charge nonionic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Definitions

  • the present invention concerns compositions and methods for treating topical inflammatory conditions, including several skin conditions, such as acne, blackheads, skin inflammation, eczema, insect bits, psoriasis, shingles, dermatitis, diaper rash, hives, pityriasis rosea, ringworm, athlete's foot, jock itch, rosacea and sunburn, and for the promotion of clear skin.
  • topical inflammatory conditions including several skin conditions, such as acne, blackheads, skin inflammation, eczema, insect bits, psoriasis, shingles, dermatitis, diaper rash, hives, pityriasis rosea, ringworm, athlete's foot, jock itch, rosacea and sunburn, and for the promotion of clear skin.
  • Acne such as acne vulgaris
  • Acne vulgaris is the most common pustular condition of the skin, disfiguring afflicted persons with inflammatory and noninflammatory lesions (including pustules, papules and comedones) during the active phase, and with atrophic scars afterwards. It occurs most commonly in teenagers, but is not confined to adolescents, as increasing numbers of people over 20 years of age are seeking advice on treatment for acne.
  • acne is generally considered to be self-limiting, its social effects can be substantial, and it may have its most severe effects on the psyche. In about 60% of teenagers, disease severity and embarrassment are sufficient for them to self-medicate with proprietary preparations and/or seek medical advice.
  • Acne is a multifactorial disease affecting the pilosebaceous units of the skin.
  • Each unit consists of a large, multilobed sebaceous gland, a rudimentary hair and a wide follicular canal lined with stratefied squamous epithelium. They are found over most of the body surface, but are largest and most numerous on the face, chest, and upper back.
  • desquamated follicular cells are carried to the surface by the flow of sebum.
  • an abnormal desquamination process provokes increased sloughing of the epithelium, which becomes more cohesive because of defective keratinization. This process causes blockage of the follicular orifice with accumulation of dead cells.
  • Androgen stimulates the undifferentiated hormonally responsive cells making up the outer layer of the sebaceous gland lobule to divide and differentiate. Sebum production favors proliferation of the anaerobe Propionibacterium acnes, which is a normal commensal to the pilosebaceous unit, which can elicit hypersensitivity responses in acne.
  • the basic lesion of acne is the microcomedo. Accumulation of sebum and keratinous debris results in a visible closed comedo, or whitehead, and its continued distension causes an open comedo, or blackhead. The dark color of blackheads is due to oxidized melanin. Blackheads and microcysts are noninflammatory lesions of acne, but some comedones evolve into inflammatory papules, pustules, or nodules, and can become chronic granulomatous lesions. The initial inflammatory cell in an acute acne papule is the CD4+T lumphocyte . Duct rupture is not a prerequisite for inflammation, which is due to the release of pro- inflammatory substances from the duct.
  • neutrophil chemotaxis When inflammation develops, neutrophil chemotaxis occurs. These neutrophils secrete hydrolytic enzymes that cause further damage and increased permeability of the follicular wall. In pustules, neutrophils are present much earlier. More persistent lesions exhibit granulomatous histology that can lead to scarring.
  • the aims of treating acne are to minimize the number and severity of lesions, prevent scarring, limit disease duration, and reduce the social and psychological stress that affects many patients, particularly teenagers.
  • Conventional treatment is directed to correcting the following three major factors that seem to cause acne: (1) androgenic stimulation of the sebaceous glands and increased sebum production; (2) abnormal keratinization and impaction in the pilosebaceous canal causing obstruction to sebum flow; and (3) proliferation of P. acnes.
  • topical agents that remove comedones such as topical retinoids are particularly effective because they normalize desquamination within the follicular orifice, which allows the sebum to flow freely onto the surface of the skin.
  • Adalpalene, tretinoin, and tazarotene have been shown to have efficacy in treating mild to moderate acne, but all three have reported to have skin-irritating side effects including erythema, pruritis, burning/stinging, and scaling/flaking (Physicians' Desk Reference ® , 56th ed., 2002, p. 2523).
  • the side effects of retinoid use are so extreme that many individuals cannot tolerate topical application of these agents at all.
  • Isotretinoin (“ACCUTANE”) is a powerful drug in the treatment of acne, but is known to cause significant side effects, such as liver damage, birth defects, chapped lips, dry skin, irritation of the eyes, joint and muscle pain, rash, intestinal symptoms, urinary symptoms, headache, increased sensitivity to sunburn, decreased night vision, increase in the level of blood fats and depression.
  • Salicylic acid and benzoyl peroxide have been used to treat acne for some time. Both agents dry the skin, which helps in acne management, but they cause some skin irritation in perilesional skin areas of acne patients, especially patients with sensitive skin, and in some cases the erythema is extreme. Moreover, it has been recently reported that benzoyl peroxide seems to induce free radical production that can produce skin changes that qualitatively resemble ultraviolet B damage, e.g., increases in epidermal thickness, and deleterious changes in elastin and glycosaminoglycan content. Topical and oral antibiotics (especially tetracycline, erythromycin, and clindamycin) are sometimes prescribed for patients with inflammatory papules and pustules. However, in addition to the undesirability of antibiotic overuse in general, which can lead to enhanced susceptibility to infection, disadvantages to such treatments include phototoxicity and interactions with other medications.
  • Treatments for acne are disclosed in USP 7,125,882 to Perricone, USP 7,129,275 to Lee et al . and USP 7,018,396 to Sierra et al .
  • Eczema is a form of dermatitis, or inflammation of the upper layers of the skin.
  • the term eczema is broadly applied to a range of persistent or recurring skin rashes characterized by redness, skin edema, itching and dryness, with possible crusting, flaking, blistering, cracking, oozing or bleeding. Areas of temporary skin discoloration sometimes characterize healed lesions, though scarring is rare.
  • eczema refers to a set of clinical characteristics. Classification of the underlying diseases has been haphazard and unsystematic, with many synonyms used to describe the same condition. A type of eczema may be described by location (e.g., hand eczema), by specific appearance (eczema craquele or discoid) , or by possible cause (varicose eczema) . Further adding to the confusion, many sources use the term eczema and the term for the most common type of eczema (atopic eczema) interchangeably.
  • More common eczemas include the following:
  • Atopic eczema is believed to have a hereditary component, and often runs in families whose members also have hay fever and asthma. An itchy rash is particularly noticeable on the face, scalp, neck, inside of elbows, behind knees, and buttocks. Experts are urging doctors to be more vigilant in weeding out cases that are in actuality irritant contact dermatitis. It is very common in developed countries, and rising.
  • Contact dermatitis is of two types: allergic (resulting from a delayed reaction to some allergen, such as poison ivy or nickel) , and irritant (resulting from direct reaction to, say, a solvent) .
  • Some substances act both as an allergen and an irritant (e.g., wet cement) .
  • Other substances cause a problem after sunlight exposure, bringing on phototoxic dermatitis.
  • About three quarters of cases of contact eczema are of the irritant type, which is the most common occupational skin ⁇ disease .
  • Contact eczema may be curable provided the offending substance can be avoided, and its traces removed from one's environment.
  • Xerotic eczema is dry skin that becomes so serious it turns into eczema. It worsens in dry winter weather, and the limbs and trunk are most often affected. The itchy, tender skin resembles a dry, cracked, river bed. This disorder is very common among the older population. Itchthyosis is a related disorder. Seborrhoeic dermatitis causes dry or greasy scaling of the scalp and eyebrows. Scaly pimples and red patches sometimes appear in various adjacent places. In newborns, it causes a thick, yellow crusty scalp rash called cradle cap, which seems related to lack of biotin, and is often curable.
  • Dyshidrosis occurs only on palms, soles and sides of fingers and toes. Tiny opaque bumps called vesicles, thickening, and cracks are accompanied by itching which gets worse at night. A common type of hand eczema, it worsens in warm weather.
  • Discoid eczema is characterized by round spots of oozing or dry rash, with clear boundaries, often on the lower legs. It is usually worse in winter. The cause is unknown, and the condition tends to come and go.
  • Venous eczema occurs in people with impaired circulation, varicose veins and edema, and is particularly common in the ankle area of people over 50. This is a redness, scaling, darkening of the skin and itching. The disorder predisposes to leg ulcers.
  • Dermatitis herpetiformis causes intensely itchy and typically symmetrical rash on the arms, thighs, knees and back. It is directly related to celiac disease, and can often be put into remission with appropriate diet.
  • Neurodermatitis is an itchy area of thickened, pigmented eczema patch that results from habitual rubbing and scratching. Usually there is only one spot. It is often curable through behavior modification and anti- inflammatory medication. Prurigo nodularis is a related disorder showing multiple lumps.
  • eczema involved the use of emollients, corticosteroids (which can cause the skin to thin and become fragile or cause bone demineralization (osteoporosis) ) , immunomodulators (pimecrolimus) and tacrolimus (which may cause lymph node or skin cancer) and antibiotics .
  • Psoriasis is an immune-mediated disease which affects the skin and joints. It commonly causes red scaly patches to appear on the skin.
  • Types of psoriasis include the following:
  • Plaque psoriasis (psoriasis vulgaris) is the most common form of psoriasis. It affects 80 to 90% of people with psoriasis. Plaque psoriasis typically appears as raised areas of inflamed skin covered with silvery white scaly skin. These areas are called plaques.
  • Flexural psoriasis (inverse psoriasis) appears as smooth inflamed patches of skin. It occurs in skin folds, particularly around the genitals, the armpits, and under the breasts. It is aggravated by friction and sweat and is vulnerable to fungal infections.
  • Guttate psoriasis is characterized by numerous small oval (teardrop-shaped) spots. These numerous spots of psoriasis appear over large areas of the body, such as the trunk, limbs and scalp. Guttate psoriasis is associated with streptococcal throat infection.
  • Pustular psoriasis appears as raised bumps that are filled with non- infectious pus (pustules) .
  • the skin under and surrounding pustules is red and tender.
  • Pustular psoriasis can be localized, commonly to the hands and feet (palmoplantar pustulosis) , or generalized with widespread patches occurring randomly on any part of the body.
  • Erythrodermic psoriasis involves the widespread inflammation and exfoliation of the skin over most of the body surface. It may be accompanied by severe itching, swelling and pain. It is often the result of an exacerbation of unstable plaque psoriasis, particularly following the abrupt withdrawal of systemic treatment. This form of psoriasis can be fatal, as the extreme inflammation and exfoliation disrupt the body's ability to regulate temperature and for the skin to perform barrier functions.
  • Ointment and creams containing coal tar, dithranol (anthralin) , corticosteroids, vitamin D 3 analogues (for example, calcipotroil) , and retinoids have been routinely used to treat psoriasis. Such creams often result in irritation of normal skin.
  • Psoriasis which is resistant to topical and phototherapy is treated by medications that are taken internally by pill or injection. This is called systemic treatment. Patients undergoing systemic treatment are required to have regular blood and liver function tests because of the toxicity of the medication.
  • Herpes zoster colloquially known as shingles, is the reactivation of varicella zoster virus (one of the Herpesviridae group) , leading to a crop of painful blisters over the area of a dermatome .
  • antiviral drugs such as aciclovir (Zovirax) , famciclovir (Famvir) or valaciclovir (Valtrex) .
  • aciclovir Zaovirax
  • famciclovir famciclovir
  • valaciclovir valaciclovir
  • Pityriasis rosea is a skin disease marked by patches of pink, oval rash. Pityriasis rosea can affect members of either sex or any age. However it is most common in females and those between the ages of 8 and 35.
  • Ultraviolet light treatment or phototherapy may shorten the duration of the condition and may be prescribed for extensive and persistent cases of pityriasis. Corticosteroid creams may also be prescribed to relieve the itching associated with pityriasis rosea.
  • Tinea is a fungus that can grow on the skin, hair or nails. As it grows, it spreads out in a circle, leaving normal -looking skin in the middle. This makes it look like a ring. At the edge of the ring, the skin is lifted up by the irritation and looks red and scaly. These infections are usually treated with anti -fungal creams, sprays or ointments.
  • Rosacea is a common chronic skin condition characterized by a spectrum of clinical indications including flushing episodes, erythema, telangiectasia, inflammatory papulopustular eruptions resembling acne, and ocular symptoms. Although accurate incidence data for the United States are not available, data obtained in Sweden suggest that some form of rosacea may be present in up to 10% of the average population. Sufferers are mostly of European origin, generally with fair skin and blue eyes . Women are more prone to develop rosacea than men, with flushing episodes and erythema being the most common symptoms found.
  • rosacea The etiology of rosacea is unknown, but it is presumed to be a genetically determined anamalous vascular response that develops in the third to sixth decades of life.
  • the hypothesis that the basis pathogenesis of the disease is a flushing disorder is based on several findings. The disease appears to be more prevalent in northern climates where cold exposure is experienced more often, and in light-skinned persons in whom flushing is common and sensitivity to sunlight is particularly high. Accordingly, rosacea may represent a type of hypersensitivity reaction disease in which vascular sensitivity is a central mechanism in its etiology. The correlation between sensitive blood vessels and sensitive skin has, however, not yet been determined.
  • rosacea The key to successful management of rosacea is early diagnosis and treatment. Treatment is generally aimed at controlling the symptoms and making the skin look better. At the present time, rosacea cannot be cured, though the frequency of its flare-ups may be diminished and their severity alleviated. Most cases of rosacea can be controlled with anti- inflammatory medications, combined with the avoidance of lifestyle and environmental factors that may aggravate the disorder in individual cases. Treatment generally works best at improving the pimples and bumps of rosacea; the redness of the skin is harder to treat. Therapeutic agents for inflammatory rosacea conditions are generally classified in the following two groups: (1) systemic and topical antibiotics; and (2) retinoids.
  • Retinoids include tretinoin (vitamin A or retinoic acid) , which is applied topically to inhibit follicular keratinization, and isotretinoin (13-cis-retinoic acid) ("ACCUTANE”), which is administered systemically to suppress activity of the sebaceous glands.
  • Retinoids are often irritants and are not advised for individuals with sensitive skin. Retinoids can also be phototoxic and they can induce thin and easily bruisable, fragile skin.
  • Metronidazole (5-methyl-5-nitromidazole-l-ethanol) , an antibacterial, is currently one of the more frequently prescribed treatments for rosacea in the United States. It is available as a topical cream under the name MetrogelTM from Galderma. Metronidazole is structurally similar to some materials which are believed to be carcinogens and is, in fact, listed by the U.S. Environmental Protection Agency as reasonably anticipated to be a human carcinogen. See the Merck Index, 1996, page 1051.
  • a safe substance such as micronized cellulose acetate phthalate (cellulose acetate 1 , 2-benzenedicarboxylate or "CAP") .
  • United States patent application Serial No. 11/494,722 filed July 27, 2006 discloses a method for treating topical inflammatory conditions, such as eczema, psoriasis, acne, shingles and insect bites, comprising topically administering a composition comprising micronized hydroxypropyl methylcellulose acetate succinate.
  • topical inflammatory conditions such as eczema, psoriasis, acne, shingles and insect bites
  • CAP microbicide cellulose acetate 1,2- benzendicarboxylate
  • the soluble CAP in the Fichorova et al . publication is not very stable and, when it is refrigerated, it is stable for only a month.
  • the substance described in the Fichorova et al . publication has a maximum of only 3 weight % CAP.
  • Cellulose acetate phthalate has heretofore been disclosed for a method for decreasing the frequency of transmission of viral infections (USP 5,985,313); decreasing the frequency of transmission of human cytomegalovirus, human immunodeficiency virus or herpesvirus, or preventing the transmission or for treating a sexually transmitted bacterial infection (USP 6,165,493); and treating or preventing bacterial vaginosis (USP 6,462,030) .
  • USP 6,572,875 and USP 6,596,297 disclose a biodegradable microbicidal vaginal barrier device comprising micronized cellulose acetate phthalate.
  • US 2005/0070501 discloses a water dispersible film comprising cellulose acetate phthalate for preventing HIV infection, treating bacterial vaginosis or preventing a non- viral sexually transmitted disease such as Chlamydia trachomatis, Neisseria gonnorrhoeae, Haemophilus ducreyi and Tre Althougha pallidum. Summary of the Invention
  • topical inflammatory conditions including various skin conditions, such as acne, blackheads, skin inflammation, eczema, insect bites, psoriasis, shingles, dermatitis, diaper rash, hives, pityriasis rosea, ringworm, athlete's foot, jock itch, rosacea and sunburn.
  • a pharmaceutical composition for topical administration to a human which includes micronized cellulose acetate 1,2- benzenedicarboxylate in a water suspension.
  • the composition containing 10 to 20 weight % cellulose acetate 1,2- benzenedicarboxylate, 10 to 15 weight % polyethylene- polypropylene glycol and 2 to 3 weight % hydroxypropylmethyl cellulose, with the remainder being water.
  • a method for treating a topical inflammatory condition by topically administering to a human in need thereof a pharmaceutically effective amount of the aforesaid composition, which includes micronized cellulose acetate 1,2- benzenedicarboxylate in a water suspension.
  • a method for treating acne, blackheads, eczema, insect bites, psoriasis, shingles, dermatitis, diaper rash, hives, pityriasis rosea, ringworm, athlete's foot, jock itch, ringworm, rosacea and sunburn by topically administering to a human in need thereof a pharmaceutically effective amount of the aforesaid composition, which includes micronized cellulose acetate 1, 2-benzenedicarboxylate in a water suspension.
  • the present invention is based on the discovery of a composition including micronized cellulose acetate 1,2- benzenedicarboxylate in a water suspension (such as "AQUACOAT", FMC BioPolymer, Philadelphia, PA, USA), is a remarkable promoter of skin health. Without wishing to be bound by any particular theory of operability, it is considered that such composition has the ability to control skin inflammation caused by some internal bodily function by interacting with the surface of the skin.
  • composition of the invention comprises:
  • composition comprises:
  • Non-limiting examples of preservatives that can be used in the aforesaid composition include ascorbic acid, methyl paraben, ethylparaben, propylparaben, benzoic acid, sorbic acid, sodium benzoate, and potassium sorbate .
  • the total amount of preservatives ranges from 0.05 to 0.3 weight %, preferably 0.1 to 0.3 weight %.
  • the topical compositions of the present invention can comprise additional ingredients found in skin care compositions, such as tinting (coloring) agents, fragrances and antioxidants, such as vitamin C or vitamin C derivatives, such as fatty acid esters of ascorbic acid, such as ascorbyl palmitate, butylated hydroxyanisole (BHA) and propyl gallate.
  • the cellulose acetate 1 , 2-benzenedicarboxylate in the composition is micronized so as to be less than 10 microns in size, and preferably approximately 1 micron in size (i.e., slightly larger than the size of bacteria) .
  • the cellulose acetate 1, 2-benzenedicarboxylate is micronized to a size of 1 to 10 microns.
  • the pH of the topical composition is approximately 2.5 to 3.
  • the topical composition has no known toxicity problems and has a mild odor, which lasts only for a short time. Such odor can be reduced or eliminated by the use of a fragrance.
  • a colorant or glycerine can be added.
  • the topical composition of the present invention serves to treat topical inflammatory conditions, such as the following skin conditions: acne, blackheads, eczema, insect bites, psoriasis, shingles, dermatitis, diaper rash, hives, pityriasis rosea, ringworm, athlete's foot, jock itch, rosacea and sunburn.
  • topical inflammatory conditions such as the following skin conditions: acne, blackheads, eczema, insect bites, psoriasis, shingles, dermatitis, diaper rash, hives, pityriasis rosea, ringworm, athlete's foot, jock itch, rosacea and sunburn.
  • the composition (cream) serves to smooth and even the complexion.
  • acne can be treated by the composition of the present invention: acne aggregata, bromide acne, common acne, congoblate acne, acne cosmetica, acne dtergicans, acne ephbica, acne fulminans, acne furunculoid, halogen acne, acne indurate, acne keloid, mechanical acne, acne medicamentosa, acne necrotica miliaris, acne neonatorum, acne oil, acne papulosa, pomade acne, premenstrual acne, acne rosacea, acne sycosiformis, tropical acne, acne venenata and acne vulgaris.
  • Non-limiting examples of dermatitis that can be treated by the topical composition of the present invention include atopic dermatitis, contact dermatitis, pemphigus dermatitis, seborrhic dermatitis, dermatitis herpetiformis and neurodermatitis .
  • Non-limiting examples of eczema that can be treated by the topical composition of the present invention include atopic eczema, xerotic eczema, dyshidrosis, discoid eczema and venous eczema.
  • Non-limiting examples of psoriasis that can be treated by the topical composition of the present invention include plaque psoriasis, flexural psoriasis, guttate psoriasis, pustular psoriasis and erythrodermic psoriasis.
  • the topical composition according to the invention is applied in a pharmaceutically effective amount, for example, in an amount of 0.5 to 5 mg/cm 2 .
  • composition of the present invention is topically applied to the affected skin areas as needed, or at predetermined intervals. It is generally the case that improvement is noted with each successive application.
  • the topical composition of the present invention is well -tolerated by the skin.
  • topical composition of the present invention does not require a pharmaceutical prescription.
  • the use of the topical composition of the present invention on the face results in a clearer, smoother appearing complexion and a healthier look.
  • non-limiting examples of the at least one pharmacologically acceptable solvent include dimethylsulfoxide or a combination of ethyl acetate and ethanol . If a combination of ethyl acetate and ethanol are used, the ethyl acetate is preferably in an amount of 90 to 95 vol% and the ethanol is preferably in an amount of 5 to 10 vol%.
  • Example 2 Formulation of the Composition
  • This example illustrates the efficacy of using the topical composition of the present invention.
  • composition as described in Example 2 above was successful in treating acne (12 people) , eczema (2 people) , insect bites (5 people) , and at a more extreme level of pain and discomfort psoriasis (1 person) and shingles (1 person) .
  • People treated for acne had all or most blackheads fall out or wash out easily, and had a general improvement in their complexions. The only complaint was a slight odor, which lasted for a short time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique pour l'administration topique à un humain comprenant 10 à 20 % en poids de 1,2-benzènedicarboxylate d'acétate de cellulose micronisé, 10 à 15 % en poids de polyéthylène-polypropylèneglycol, 2 à 3 % en poids d'hydroxypropylméthylcellulose, et l'équilibre étant l'eau. La composition est utile pour traiter l'acné, les points noirs, l'inflammation cutanée, l'eczéma, les piqûres d'insecte, le psoriasis, les zonas, la dermatite, l'érythème fessier, les colonies, le pityriasis rosé de Gibert, la teigne, le pied d'athlète, l'eczéma marginé de Hébra, l'acné rosacée et les coups de soleil.
PCT/US2008/001542 2007-03-01 2008-02-06 Cosmétique de 1,2-benzènedicarboxylate d'acétate de cellulose Ceased WO2008108908A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90423307P 2007-03-01 2007-03-01
US60/904,233 2007-03-01

Publications (2)

Publication Number Publication Date
WO2008108908A2 true WO2008108908A2 (fr) 2008-09-12
WO2008108908A3 WO2008108908A3 (fr) 2009-12-23

Family

ID=39738961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/001542 Ceased WO2008108908A2 (fr) 2007-03-01 2008-02-06 Cosmétique de 1,2-benzènedicarboxylate d'acétate de cellulose

Country Status (1)

Country Link
WO (1) WO2008108908A2 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1542695A1 (fr) * 2002-09-17 2005-06-22 Nippon Boehringer Ingelheim Co., Ltd. Composition pharmaceutique pour l'administration topique de meloxicam, qui contient une amine ou un amide comme agent facilitant la penetration
US8349819B2 (en) * 2002-10-09 2013-01-08 Dr. Reddy's Laboratories New York, Inc. Steroid extraction process from urine sources
US9211259B2 (en) * 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
EP1680094A1 (fr) * 2003-09-26 2006-07-19 Alza Corporation Preparations a liberation regulee a base d'analgesiques opioides et non opioides
US20060062866A1 (en) * 2004-09-21 2006-03-23 New York Blood Center, Inc. Starch-pomegranate juice complex as an HIV entry inhibitor and topical microbicide
IL166646A0 (en) * 2005-01-30 2006-01-15 Or Le Or Ltd A new cosmetic composition

Also Published As

Publication number Publication date
WO2008108908A3 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
Tüzün et al. Rosacea and rhinophyma
KR100619228B1 (ko) 국소피부전달 무수조성물 및 상기 조성물을 약제로 포함하는 국소 피부 치료용 조성물
JP5538434B2 (ja) 皮膚疾患を治療または予防するための、アベルメクチンまたはミルベマイシンとアドレナリン受容体との組合せ
CN105792829A (zh) 使用伊维菌素治疗丘疹脓疱性红斑痤疮
EA032439B1 (ru) Композиции и способы для лечения поверхностных ран
CA2822320A1 (fr) Composition pour le traitement d'etats pathologiques de la peau
PT1439832E (pt) Processo para tratar a acne vulgaris utilizando um composto de avermectina
CN102159198A (zh) 皮肤感染的局部治疗
TW201818944A (zh) 氧化膽固醇硫酸鹽（ｏｃｓ）於治療炎性皮膚疾病及皮膚病灶之用途
CN108283620A (zh) 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
WO2012095719A1 (fr) Mélatonine et agent antimicrobien ou antibactérien pour traiter l'acné acne
Al-Khikani Amphotericin B, the wonder of today’s pharmacology science: persisting usage for more than seven decades
US8673356B2 (en) Stable fixed dose topical formulation
US20200261401A1 (en) Method for treatment of rosacea including patient reported outcomes thereof
US9144612B2 (en) Dermatological compositions containing an association of peroxide lipids and zinc, and uses thereof in particular in the treatment of labial and/or genital herpes
US20050089485A1 (en) Sulfacetamide formulations for treatment of rosacea
US10960011B2 (en) Compositions for the treatment of ischemic ulcers and stretch marks
WO2008108908A2 (fr) Cosmétique de 1,2-benzènedicarboxylate d'acétate de cellulose
US9642877B1 (en) Method of administration of chromium and magnesium sulfate for treatment of acne
Öztürk et al. Pharmacological and pharmaceutical technological overview for seborrheic dermatitis: A review about topical application and new approaches
US20190054045A1 (en) Methods and compositions for treating skin conditions
Buchanan et al. Prescribing in dermatology
Lee Van L. Tran, PharmD, BCPS, BCPPS, MBA, FPPA
CN116392489A (zh) 抗病毒感染性皮肤病的药物组合物及其制剂和应用
JP2024128672A (ja) 顔の皮膚状態の改善剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08725207

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08725207

Country of ref document: EP

Kind code of ref document: A2